Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab for Colon Adenoma Prevention in Lynch Syndrome
NCT03631641Phase 2Terminated
- Sponsor
- Hays
- Start
- Oct 2018
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in colon adenoma and colorectal cancer (CRC), sponsored by Hays. Primary endpoints: Incidence Rate of Adenomas at 3 years, Incidence Rate of High-risk Adenomas at 3 years and 2 more. Started Oct 2018; status: terminated.
02
Drugs
03
Conditions
colon adenomacolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03631641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631641.